A chimeric peptide unique in the world
Our lead product AmyP53 is a chimeric peptide (Alzheimer's / Parkinson's) generated through an innovative strategy of artificial intelligence applied to the molecular neuroscience. AmyP53 is capable of blocking the formation of neurotoxic structures (oligomers of amyloid proteins) responsible for these two neurodegenerative diseases (new therapeutic target, the only molecule in the world capable of acting on Alzheimer's and Parkinson's).
Our drug candidate is thus the first representative of a new therapeutic class that inhibits a fundamental mechanism common to Alzheimer's and Parkinson's diseases.
The scientific discoveries behind AmyPore project are the result of the work of two passionate and internationally recognized university professors, Nouara Yahi (Aix-Marseille University) and Jacques Fantini (Aix-Marseille University and Institut Universitaire de France, https://jfantini.jimdo.com), who cumulate together more than 300 publications in well-known scientific journals. Nouara Yahi and Jacques Fantini own the intellectual property of the patent, and AmyPore has an exclusive license to develop AmyP53 as an anti-Alzheimer and Parkinson medicine.
AmyPore has been incubated by Kedge Business Nursery. AmyPore has been also affiliated with OneLife and Impulse. The company is also supported by the European Commission (H2020 SME Phase 1).